Patient Guide: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 207 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06170788
Status: 🟢 Enrolling Now
Condition: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase: PHASE3

Where You Can Participate

This study is available at 207 locations across the country.

Top locations include:
  • • Burbank, California
  • • Grand Junction, Colorado
  • • Marietta, Georgia
  • • And 204 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - Join Clinical Trial NCTNCT06170788

How to Join This Clinical Trial - NCTNCT06170788

Learn how to participate in this PHASE3 trial studying an investigational therapy for Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06170788 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 207 locations. Find a study site near you:

Clinical Research Site

Burbank, California 91505 - United States

Status: RECRUITING

Clinical Research Site

Grand Junction, Colorado 81501 - United States

Status: RECRUITING

Clinical Research Site

Marietta, Georgia 30060 - United States

Status: COMPLETED

Clinical Research Site

Louisville, Kentucky 40202 - United States

Status: RECRUITING

Clinical Research Site

Westbrook, Maine 04092 - United States

Status: RECRUITING

Clinical Research Site

Worcester, Massachusetts 01655 - United States

Status: COMPLETED

Clinical Research Site

Minneapolis, Minnesota 55407 - United States

Status: RECRUITING

Clinical Research Site

Hattiesburg, Mississippi 39401 - United States

Status: RECRUITING

Clinical Research Site

Reno, Nevada 89502 - United States

Status: RECRUITING

Clinical Research Site

Cleveland, Ohio 44106 - United States

Status: RECRUITING

And 197 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Lung Neoplasms, Carcinoma, Non-Small-Cell Lung:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships